GL1X · GenesisL1 explorer

Research workbench

Trimeric SARS-cov-2 spike ectodomain in complex with biliverdin (one rbd erect)

Analyse Trimeric SARS-cov-2 spike ectodomain in complex with biliverdin (one rbd erect) in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7NTA
Type
protein
Length
3,261 residues
Chains
3
Method
electron microscopy
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Spike glycoprotein
UniProt
P0DTC2
Ligands
BLA, NAG
Pockets
20 · best druggability 0.88

Structure

electron microscopy · 1 distinct chain · 20% helix, 31% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
B, C, ASpike glycoproteinprotein108720% helix, 31% strandP0DTC2

Ligands and binding sites

  • BLA · Biliverdine IX alpha · ligand · 3 copies · chains B, C, A
  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 77 copies · chains B, C, A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

20 pockets found on a 1 Å grid, 20 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
19870.880.89116empty
210200.870.88119empty
310530.850.86111empty
48570.830.8688empty
56740.750.8145empty

Interfaces

3 interfaces between chains.

  • B–C · 4895 Ų buried · 38 hydrogen bonds · protein-protein
  • B–A · 4772 Ų buried · 39 hydrogen bonds · protein-protein
  • C–A · 4298 Ų buried · 22 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 53 glycan, 42 disulfide (N-glycosylation, disulfide, glycosylation).

Compared structures

  • 7NTA · Trimeric SARS-CoV-2 spike ectodomain in complex with biliverdin (one RBD erect) · the same entry in another collection · chain B against B, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.